TAKEDA RECEIVES U.S. FDA APPROVAL OF MIMRYLO™ (RUSFERTIDE), MARKING A POTENTIAL SHIFT IN THE TREATMENT PARADIGM FOR POLYCYTHEMIA VERA

Reuters · 1d ago

Please log in to view news